Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients

J Neurol. 2021 Nov;268(11):4376-4378. doi: 10.1007/s00415-021-10679-3. Epub 2021 Jun 28.

Authors

Souraya El Sankari¹, Cyril Van Essche², Vincent van Pesch³

Affiliations

¹ Department of Neurology, Cliniques Universitaires Saint-Luc, UClouvain, Brussels, Belgium.
² Department of Anatomopathology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
³ Department of Neurology, Cliniques Universitaires Saint-Luc, UClouvain, Brussels, Belgium. vincent.vanpesch@uclouvain.be.

PMID: 34181076
DOI: 10.1007/s00415-021-10679-3

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Female
Humans
Immunologic Factors / therapeutic use
Male
Middle Aged
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Chronic Progressive*
Multiple Sclerosis, Relapsing-Remitting*
T-Lymphocytes

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
ocrelizumab